CATX (Perspective Therapeutics) Minority Interest : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Perspective Therapeutics's minority interest for the quarter that ended in Sep. 2024 was $0.00 Mil.

Perspective Therapeutics Minority Interest Historical Data

The historical data trend for Perspective Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics Minority Interest Chart

Perspective Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Dec23

Minority Interest

Get a 7-Day Free Trial

Perspective Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

Perspective Therapeutics Minority Interest Calculation

Perspective Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

AAJ0:Germany AAJ0:Germany

Address

2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121

Website

https://www.perspectivetherapeutics.com

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Executives

Johan M. Spoor	director, officer: CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Jonathan Robert Hunt	officer: Chief Financial Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Williamson Robert F Iii	director	140 LASALLE AVENUE, PIEDMONT CA 94610
Lori A Woods	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Markus Puhlmann	officer: Chief Medical Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Mark John Austin	officer: Controller/Prin Fin&Acct Offic	350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale	director	8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick	director	9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann	director	3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon	officer: VP of Sales & Marketing	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline	officer: Dir. of Operations, Secretary	350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter	officer: VP of Human Resources	350 HILLS STREET SUITE 106, RICHLAND WA 99354